India Business News: Sentynl, under Zydus Lifesciences, acquired global rights for Zokinvy, the first FDA-approved Progeria treatment. An acquisition milestone in expandin
Bayer Pharmaceuticals Private Limited and Zydus Lifesciences Limited have concluded their joint venture, Bayer Zydus Pharma Private Limited (BZPPL), established in 2011 for pharmaceutical sales and marketing in India. Bayer is now acquiring full ownership of the entity as per pre-agreed terms. The joint venture successfully combined Zydus s Indian marketing expertise and distribution network with Bayer s global innovation, making strides in various therapeutic areas.
Foram Parekh shares insights on CDMO companies positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about Laurus s earnings improvement, Sun Pharma s specialty sales focus, and recommendations for pharma sector growth with Lupin and Dr Reddy s.
Zydus will enter a competitive field, with an FDA decision on CymaBay s PBC drug due in August. Gilead Sciences announced its acquisition of CymaBay for $4.3 billion earlier in February. Saroglitazar, currently in a mid-to-late-stage trial for PBC, is also being tested for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a type of fatty liver disease."